Vemurafenib
- Generic Name
- Vemurafenib
- Brand Names
- Zelboraf
- Drug Type
- Small Molecule
- Chemical Formula
- C23H18ClF2N3O3S
- CAS Number
- 918504-65-1
- Unique Ingredient Identifier
- 207SMY3FQT
- Background
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...
- Indication
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...
- Associated Conditions
- Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
- Associated Therapies
- -
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 43
- Registration Number
- NCT01636908
- Locations
- 🇳🇱
VUMedical Center, Amsterdam, Netherlands
Study of Vemurafenib, Carboplatin, and Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01636622
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01616199
- Locations
- 🇺🇸
New York University, New York, New York, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT01611675
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01603212
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 704
- Registration Number
- NCT01597908
- Locations
- 🇬🇧
Novartis Investigative Site, Swansea, United Kingdom
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01596140
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01586195
- Locations
- 🇺🇸
Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Oncology Specialists, S.C., Park Ridge, Illinois, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT01585415
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT01531361
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.